[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"secukinumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:secukinumab":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100613014","phase-4-comparison-of-the-clinical-efficacy-and-safety-of-topical-and-subcutaneous-injection-of-secukinumab-in-hs-100613014",false,"NCT07261072","Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS","Comparison of the Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS: A Prospective Exploratory Trial","Inclusion Criteria:\n\n1. Meet international diagnostic criteria for hidradenitis suppurativa\n2. Aged ≥ 18 years\n3. Disease duration ≥ 6 months and resistance to conventional therapy (no significant improvement for ≥ 3 months)\n4. Lesions were confined to a single anatomical area\n5. Voluntarily signed the informed consent form and was able to cooperate in all visits and examinations.\n\nExclusion Criteria:\n\n1. Hypersensitivity to any component of secukinumab injection\n2. With severe vital organ failure\n3. With active infection or malignancy (malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin and cured)\n4. Treatment with biologics, immunosuppressants, or systemic corticosteroids within the last 3 months\n5. Pregnant, nursing, or planning conception during the study\n6. Mental disorders or cognitive impairment that precludes understanding of study procedures\n7. Participating in another clinical study and are at risk of an interaction between the study drugs\n8. Other conditions assessed by the investigators as inappropriate for participation in the study","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c. every 2 weeks resulted in 42% to 45% of patients achieving a clinical response (HiSCR) to HS, and the efficacy was sustained through 52 weeks.However, we found in clinical practice that some HS patients present with localized lesions (small areas of involvement, affecting only 1-2 anatomic areas) that are resistant to conventional therapy, and have not yet fulfilled surgical indications, and the need for systemic biologic therapy is controversial.Such patients often experience inadequate response or slow onset of action when they receive secukinumab by routine subcutaneous injection - possibly related to inadequate drug concentration in the focal lesional area and limited local anti-inflammatory effects after systemic administration.In addition, side effects of conventional subcutaneous injection system are greater, and the application is limited in some patients, so it is necessary to explore more appropriate and safer drug delivery method for localized skin lesions.Localized HS, local injection of lesions may enhance anti-inflammatory effects while reducing systemic exposure by increasing drug concentrations at the lesion site.Therefore, exploring novel modes of administration of secukinumab has practical clinical implications based on clinical practice needs and the context of the previous literature.In summary, by exploring the efficacy and safety of local skin injection of secukinumab, this study may provide a new strategy for the treatment of limited HS with sufficient scientific rationale and significant potential benefits and manageable risks.",[26,27,28],"Hidradenitis Suppurativa (HS)","Hidradenitis Suppurativa (Acne Inversa)","Secukinumab","NOT_YET_RECRUITING","2025-12-02",{"date":32,"type":33},"2025-12-03","ACTUAL",{"date":35,"type":20},"2025-12-01",{"date":37,"type":20},"2026-12-31",{"name":39,"class":40},"Peking Union Medical College","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100591966","a-prospective-study-to-assess-the-efficacy-of-il-17-inhibitors-on-subclinical-enthesitis-in-patients-with-moderate-to-severe-psoriasis-based-on-power-doppler-pd-ultrasonography-pdus-100591966","NCT06987292","A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)","Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS): a Single-center, Prospective, Exploratory, Open-label Study","Inclusion Criteria:\n\n1. Adult patients ( ≥ 18 years of age) with chronic plaque-type psoriasis\n2. Meet one of the following conditions: Psoriasis Area and Severity Index \\[PASI\\] score \\> 6, or scalp involvement, or nail involvement.\n3. Inflammatory changes on ultrasound consistent with OMERACT definition at least at one peripheral attachment point at screening, defined as thickening and\u002For abnormal echogenicity of tendons or ligaments at the site of their insertion into the bone (within 2 mm of the talar cortex), and active Doppler signals that may indicate structural damage such as bone erosion, syndesmophytes\u002Fcalcifications\n4. Psoriasis is inadequately controlled by current topical therapy or phototherapy\n5. Able to sign the informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of PsA2 according to CASPAR\n2. Any known rheumatic disease, positive rheumatoid factor\u002Fanti-citrullinated protein antibodies, prior treatment with anti-rheumatic drugs\n3. Treatment with systemic corticosteroids within 12 weeks or 5 half-lives of screening\n4. Obesity impeded ultrasound examination\n5. Pregnant or lactating women or women with plan for conception 5 months before or after treatment\n6. Participated in other clinical trials\n7. Concurrent significant medical problems, including but not limited to the following: uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 95 mmHg), congestive heart failure (NYHA class III or IV), total white blood cell count \\\u003C 2500\u002Fμl, or platelets \\\u003C 100,000\u002Fμl or neutrophils \\\u003C 1500\u002Fμl or hemoglobin \\\u003C 8.5 g\u002FdL at screening.\n8. Any liver function abnormality: aspartate aminotransferase (AST) \\> 2xULN, alanine aminotransferase (ALT) \\> 2xULN, total bilirubin (TBIL) \\> 2xULN\n9. Abnormal renal function: serum creatinine \\> 2.0 mg\u002Fdl\n10. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection, defined as a positive PPD skin test or Mycobacterium tuberculosis interferon-gamma release assay (IGRA) test.\n11. Current or relevant history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.\n12. History of lymphoproliferative disease, or any known malignancy, or history of malignancy of any organ system within the past 5 years\n13. Unable or unwilling to undergo repeated venipuncture\n14. History of alcohol or drug abuse or evidence of abuse within 6 months prior to baseline\n15. History of hypersensitivity to any component of the study drug\n16. Did not accept live vaccines within 4 weeks prior to enrollment, do not have plan of vaccination program during the study, and no live vaccines are planned \\> 6 months after the last dose of the study (herpes zoster vaccine \\> 12 months)",{"count":50,"type":20},50,"OBSERVATIONAL","It is an observational, single-center, prospective, exploratory, open-label study to assess the efficacy and safety of IL-17 inhibitors on subclinical enthesitis in patients with moderate to severe psoriasis with subclinical enthesitis based on Power Doppler (PD) Ultrasonography (PDUS)",[54,55,56,28],"Psoriasis (PsO)","Enthesitis","Psoriasis Arthritis","RECRUITING","2025-05-15",{"date":60,"type":33},"2025-05-23",{"date":62,"type":33},"2025-05-01",{"date":64,"type":20},"2027-12-31",{"name":66,"class":40},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},"100587269","efficacy-and-safety-of-secukinumab-in-conjunction-with-surgery-in-moderate-to-severe-hidradenitis-suppurativa-100587269","NCT06926192","Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa","Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS\n2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital\n3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital\n4. Patients with complete clinical data followed up for at least 1 year\n\nExclusion Criteria:\n\n1. Patients lost to follow-up\n2. Patients with less than one year of follow-up\n3. Patients who received additional adjuvant therapy during the follow-up period","80 Years",{"count":77,"type":20},100,"This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.",[26,27,28],"2025-04-11",{"date":82,"type":33},"2025-04-16",{"date":84,"type":33},"2020-01-01",{"date":86,"type":20},"2025-06-21",{"name":39,"class":40},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":67},"100572212","prospective-study-of-classification-and-activity-assessment-of-psoriatic-arthritis-based-on-power-doppler-pd-ultrasonography-pdus-100572212","NCT06730334","Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)","A Single Centre Prospective Cohort Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)","Inclusion Criteria:\n\n* PsA patients as defined by CASPAR criteria\n* Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures\n* Patients must be given informed consent\n\nExclusion Criteria:\n\n* History of other arthritis within the last 12 months\n* Concomitant disease with acute or chronic infectious diseases\n* Pregnancy or laction\n* Poorly tolerated with venipuncture required for blood sampling during the study",{"count":96,"type":20},400,"Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.",[99,28,100],"Psoriatic Arthritis","Ultrasonography","2024-12-18",{"date":103,"type":33},"2024-12-20",{"date":105,"type":33},"2023-09-01",{"date":107,"type":20},"2028-06-01",{"name":109,"class":40},"Nanjing Medical University"]